Duality Biologics

Duality Biologics

生物技术研究

We translate novel modality into reality!

关于我们

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物 映恩生物(Duality Biologics)是一家临床阶段的创新生物药企,专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物(ADC)技术平台。基于对疾病生物学机制的深入研究和探索,映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台,以开发下一代“超级ADC”分子,包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作,并在全球开展多个国际多中心(MRCT)关键性临床研究。致力于成为世界领先的ADC公司。 如需更多信息,请访问www.dualitybiologics.com

网站
https://www.dualitybiologics.com/
所属行业
生物技术研究
规模
51-200 人
总部
Shanghai
类型
私人持股
创立
2020
领域
ADC

地点

Duality Biologics员工

动态

相似主页

融资